Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Director | 4.67M | -- | 1971 |
| Mr. Blaine T. Davis | Chief Financial Officer | 2.49M | -- | 1974 |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer | 398.28k | -- | 1979 |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer | 296.85k | -- | 1982 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | -- | -- | -- |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer | -- | -- | 1984 |
| Dr. Emily English Ph.D. | SVP & Head of Manufacturing | -- | -- | 1980 |
Cartesian Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 66
Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma. Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.
Corporate Governance
Upcoming Events
May 6, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Cartesian Therapeutics, Inc. Earnings Date
Recent Events
January 10, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
January 6, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission